Mesuximide

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Mesuximide
Clinical data
AHFS/Drugs.comConsumer Drug Information
MedlinePlusa682028
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic (demethylation and glucuronidation)
Elimination half-life1.4–2.6 hours (mesuximide)
28–38 hours (active metabolite)
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC12H13NO2
Molar mass203.237 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Mesuximide

Articles

Most recent articles on Mesuximide

Most cited articles on Mesuximide

Review articles on Mesuximide

Articles on Mesuximide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mesuximide

Images of Mesuximide

Photos of Mesuximide

Podcasts & MP3s on Mesuximide

Videos on Mesuximide

Evidence Based Medicine

Cochrane Collaboration on Mesuximide

Bandolier on Mesuximide

TRIP on Mesuximide

Clinical Trials

Ongoing Trials on Mesuximide at Clinical Trials.gov

Trial results on Mesuximide

Clinical Trials on Mesuximide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mesuximide

NICE Guidance on Mesuximide

NHS PRODIGY Guidance

FDA on Mesuximide

CDC on Mesuximide

Books

Books on Mesuximide

News

Mesuximide in the news

Be alerted to news on Mesuximide

News trends on Mesuximide

Commentary

Blogs on Mesuximide

Definitions

Definitions of Mesuximide

Patient Resources / Community

Patient resources on Mesuximide

Discussion groups on Mesuximide

Patient Handouts on Mesuximide

Directions to Hospitals Treating Mesuximide

Risk calculators and risk factors for Mesuximide

Healthcare Provider Resources

Symptoms of Mesuximide

Causes & Risk Factors for Mesuximide

Diagnostic studies for Mesuximide

Treatment of Mesuximide

Continuing Medical Education (CME)

CME Programs on Mesuximide

International

Mesuximide en Espanol

Mesuximide en Francais

Business

Mesuximide in the Marketplace

Patents on Mesuximide

Experimental / Informatics

List of terms related to Mesuximide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]

References

  1. Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Retrieved August 21, 2006.[dead link]
  2. Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
  3. Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.

Template:Anticonvulsants